Table 4

Multivariate analyses of the determinants of FASN concentrations in HCV co-infected patients (n = 115)

β Coefficient

95% CI

P Values


Age, years

0.144

-0.409 to 1.327

0.292

Gender, male

0.134

-15.86 to 5.14

0.327

BMI, kg/m2

0.086

-0.75 to 1.677

0.444

Patients treated with PI or NNRTI, n

-0.295

-23.92 to 1.56

0.041

Lipodystrophy, n

-0.202

-18.147 to 2.19

0.121

CD4+ T cell count, cells/mm3

0.121

-0.005 to 0.19

0.260

Undetectable HIV-1 viral loada, n

0.053

-6.559 to 10.55

0.639

HDL-cholesterol, mmol/L

0.046

-12.89 to 17.55

0.759

Triglyceride, mmol/L

0.050

-2.45 to 3.49

0.726

Apolipoprotein A-I, g/L

0.230

-5.063 to 36.14

0.135

MCP-1, pg/mL

0.271

2.403 to 0.021

0.021

Insulin, pmol/L

-0.009

-0.040 to 0.037

0.937

IL-8, ng/L

0.025

-0.012 to 0.016

0.828

hsCRP, mg/L

-0.108

-1.00 to 0.328

0.312

Alanine aminotransferase, μKat/L

0.599

5.154 to 18.48

0.001

Aspartate aminotransferase, μKat/L

-0.073

-9.98 to 6.36

0.668


Dependent variable: FASN concentration (μg/L)

BMI: body-mass index; NNRTI: non-nucleoside analogues reverse transcriptase inhibitors; PI: protease inhibitors, hsCRP: high sensitive C-reactive protein.

aLimit of detection was 40 copies/mL

Aragonès et al. BMC Gastroenterology 2010 10:92   doi:10.1186/1471-230X-10-92

Open Data